Published In
Neuropsychiatric Investigation
Volume 52 · Issue -1
Pages: 32-4
History
Published Online: January 1, 2014
Copyright © 2014 Neuropsychiatric Investigation
Seden Demirci
Süleyman Kutluhan
Kadir Demirci
Arif Demirdaş
Demirci, S., Kutluhan, S., Demirci, K., & Demirdaş, A. (2014). Primidone and neuroleptic malignant syndrome; a case report. Neuropsychiatric Investigation, 52(-1), 32–4. https://doi.org/10.5455/NYS.20141009063956
Full Text
Full Text PDF
Full Text PDF
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication of treatment with antipsychotic drugs. Clinical features of NMS are muscle rigidity, hyperpyrexia, autonomic instability, mental status changes, and high level of creatine phosphokinase. Primidone is an antiepileptic drug and also used for the treatment of essential tremor. It may interact with many drugs such as antipsychotics. This report presents a 49-year-old patient who developed NMS following the abrupt discontinuation of primidone.
Similar Articles
Article Info
Published In
Journal
Neuropsychiatric Investigation
Volume / Issue
Volume 52 · Issue -1
Pages
32-4
History
Published Online
January 1, 2014
Copyright
Copyright (c) 2014 Neuropsychiatric Investigation
Affiliations
Seden Demirci
Süleyman Kutluhan
Kadir Demirci
Arif Demirdaş
Cite this Article
Demirci, S., Kutluhan, S., Demirci, K., & Demirdaş, A. (2014). Primidone and neuroleptic malignant syndrome; a case report. Neuropsychiatric Investigation, 52(-1), 32–4. https://doi.org/10.5455/NYS.20141009063956
Outlines